Carisma Therapeutics, Inc. (CARM) P/E Ratio History
Deep ValueTrading at -0.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2016–2025
Loading P/E history...
P/E Ratio Analysis
As of June 19, 2026, Carisma Therapeutics, Inc. (CARM) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.02 and trailing twelve-month earnings per share of $0.19.
The current P/E is 100% below its 5-year average of 12.2x. Over the past five years, CARM's P/E has ranged from a low of 1.4x to a high of 48.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, CARM trades at a 100% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, CARM trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CARM DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CARM Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CARM P/E vs Peers
Cell and Gene Therapy Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $37B | 119.4 | - | +207%Best | |
| $25B | 29.7Lowest | 7.02Best | +171% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CARM Historical P/E Data (2016–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | - | $0.27 | $0.20 | 1.4x | -89% |
| FY2022 Q2 | - | $16.21 | $7.34 | 2.2x | -82% |
| FY2022 Q1 | - | $12.05 | $4.81 | 2.5x | -79% |
| FY2017 Q2 | Jun 30 2017 | $31.40 | $4.42 | 7.1x | -42% |
| FY2017 Q1 | Mar 31 2017 | $44.00 | $3.82 | 11.5x | -5% |
| FY2016 Q4 | Dec 31 2016 | $38.20 | $0.79 | 48.4x | +297% |
Average P/E for displayed period: 12.2x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CARM — Frequently Asked Questions
Quick answers to the most common questions about buying CARM stock.
What is CARM's P/E ratio?
Carisma Therapeutics, Inc. (CARM) trailing twelve-month P/E ratio is -0.0x, based on TTM diluted EPS of $0.19. The 5-year average P/E is 12.2x and the historical range spans 1.4x to 48.4x.
Is CARM stock overvalued or undervalued?
CARM current P/E: -0.0x. 5-year average P/E: 12.2x. Percentile: 0th.
Is CARM stock expensive?
CARM is fairly valued relative to its own history. The current P/E of -0.0x is near the 5-year average of 12.2x (0th percentile of historical range).
What is CARM's historical P/E range?
Over the past 5 years, CARM's P/E ratio has ranged from 1.4x to 48.4x, with a median of 7.1x and an average of 12.2x. The current P/E of -0.0x places the stock at the 0th percentile of this range. Full historical data spans 2016–2025.
How does CARM's P/E compare to the S&P 500?
CARM current P/E: -0.0x. S&P 500 median P/E: 24.4x.
How does CARM's valuation compare to Healthcare peers?
Carisma Therapeutics, Inc. P/E of -0.0x can be benchmarked against Healthcare peers in the comparison table on this page.
What is CARM's PEG ratio?
CARM PEG ratio is N/A, based on a P/E of -0.0x and EPS growth of 43.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CARM's earnings yield?
CARM earnings yield is N/A, the inverse of its -0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.